Quantum Cyber NV Dossier - Source-backed chat

Quantum Cyber NV

QUCYNASDAQ

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)1.91

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.35Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $113.5M

Enterprise Value $101M

Shares Outstanding 84.1M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Quantum Cyber N.V. (formerly Mainz Biomed N.V.) has undergone a complete corporate pivot in 2026 from molecular diagnostics to an AI-powered, quantum-accelerated autonomous defense platform. While the company has secured exclusive IP licenses, signed letters of intent with defense entities, and acquired a manufacturing facility in Bridgeport, Connecticut, it remains an early-stage micro-cap with high execution risks. Furthermore, a June 2026 short-seller report by White Diamond Research highlighted severe dilution risks associated with convertible preferred stock held by the CEO, which could expand the share count to nearly 500 million. Given the early stage of the defense pivot and the overhang of potential dilution, a Hold recommendation is warranted.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.2025%

The company fails to operationalize its manufacturing facility or secure binding defense contracts. Massive dilution occurs as preferred shares are converted to common stock, flooding the market. Additionally, regulatory or technical hurdles prevent the commercialization of its quantum-accelerated technologies, leading to rapid cash burn.

Base CaseCentral scenario

$1.2050%

Quantum Cyber establishes initial production lines at its newly acquired Bridgeport facility and begins delivering on its current $2.09 million in purchase orders. The company continues to develop its QC-Core AI platform and quantum antenna technologies, but faces typical early-stage manufacturing bottlenecks and slow defense procurement cycles, keeping the stock range-bound.

Bull CaseUpside scenario

$3.0025%

The company successfully scales its domestic drone manufacturing at the Bridgeport facility to meet its target of 100,000 drones annually. It converts its non-binding letters of intent with General Cherry and SOCOM into binding, high-value procurement contracts, capitalizing on the U.S. Department of Defense's massive autonomous warfare budget expansion.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strategic alignment with the U.S. Department of Defense's massive autonomous warfare budget expansion.
Exclusive IP licensing agreements, including combat-proven drone portfolios and quantum photonic array technology.
Acquisition of a 43,000 square foot manufacturing facility in Bridgeport, Connecticut, to support domestic production.
Debt-free balance sheet with over $15 million raised from completed warrant exercises.

Key Investment Risks

Extreme dilution risk from convertible preferred stock held by CEO David Lazar (up to 477 million shares).
High execution and operational risk associated with pivoting from diagnostics to defense manufacturing.
Speculative nature of early-stage quantum-accelerated technologies and potential failure to achieve commercial scale.
Dependence on non-binding letters of intent and highly competitive government procurement processes.

Thesis Invalidation Triggers

Failure to complete the operational setup or begin production at the Bridgeport facility by late 2026.
Mass conversion and subsequent market dumping of the CEO's preferred shares.
Cancellation or failure to convert existing letters of intent with defense partners into binding contracts.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.